Acumen Pharmaceuticals, Inc. — Director's Dealing 2024

Feb 1, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2024-02-01

Reporting Person: Doherty James J. (President and CDO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-01	Employee Stock Option (right to buy)	$3.11	A	601000	Acquired	2034-02-01	Common Stock (601000)	Direct

Footnotes

F1: Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on February 1, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.